Recent News

• 06.11.2025 - Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
• 06.11.2025 - Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
• 06.05.2025 - Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
• 06.05.2025 - Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
• 05.13.2025 - Tempest Reports First Quarter 2025 Financial Results and Provides Business Update
• 05.13.2025 - Tempest Reports First Quarter 2025 Financial Results and Provides Business Update
• 04.28.2025 - Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
• 04.28.2025 - Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
• 04.21.2025 - Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
• 04.21.2025 - Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Recent Filings

• 06.11.2025 - 8-K Current report
• 06.06.2025 - 8-K Current report
• 05.13.2025 - EX-99.1 EX-99.1
• 05.13.2025 - 8-K Current report
• 05.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.30.2025 - 10-K/A Annual report [Section 13 and 15(d), not S-K Item 405]
• 04.28.2025 - 8-K Current report
• 04.18.2025 - 8-K Current report